Stoke Therapeutics(STOK) - 2025 Q3 - Quarterly Results

Financial Performance - Revenue for Q3 2025 was $10.6 million, an increase of 116.3% from $4.9 million in Q3 2024, driven by agreements with Acadia and Biogen[9] - Revenue for the nine months ending September 30, 2025, was $183.0 million, a significant increase from $13.9 million for the same period in 2024[9] - Net income for the nine months ended September 30, 2025, was $51.0 million, or $0.85 per diluted share, compared to a net loss of $78.5 million, or $1.48 per share, for the same period in 2024[9] - Revenue for Q3 2025 was $10,632,000, a 117% increase compared to $4,894,000 in Q3 2024[25] Expenses and Losses - Net loss for Q3 2025 was $38.3 million, or $0.65 per share, compared to a net loss of $26.4 million, or $0.47 per share, for the same period in 2024[9] - Total operating expenses for Q3 2025 were $53,723,000, up from $34,897,000 in Q3 2024, representing a 54% increase[25] - Research and development expenses for Q3 2025 increased to $37.7 million from $22.2 million in Q3 2024, reflecting increased activities to support zorevunersen[9] - Research and development expenses for the nine months ended September 30, 2025, were $96,227,000, an increase from $65,710,000 in the same period of 2024[25] Cash and Assets - As of September 30, 2025, the company had $328.6 million in cash, cash equivalents, and marketable securities, expected to fund operations until mid-2028[9] - Cash and cash equivalents as of September 30, 2025, were $83,394,000, down from $127,983,000 as of December 31, 2024[23] - Total assets increased to $360,264,000 as of September 30, 2025, compared to $271,555,000 as of December 31, 2024[23] - Stockholders' equity rose to $308,105,000 as of September 30, 2025, from $229,021,000 as of December 31, 2024[23] Clinical Development - The global Phase 3 EMPEROR study is actively recruiting patients, with more than 20 patients randomized and approximately 35 additional patients in the screening period[3][4] - The company plans to present new data from the zorevunersen clinical development program at the American Epilepsy Society 2025 Annual Meeting in December[6] - The company is scheduled to meet with the FDA before year-end 2025 to discuss zorevunersen's safety and efficacy data under the Breakthrough Therapy Designation[6] Collaborations - The company is collaborating with Biogen and Acadia for the development of zorevunersen and STK-002[19] - The company sold approximately 1.8 million shares of common stock since September 30, 2025, raising $48.7 million after commissions[9] Interest Income - The company reported interest income of $3,463,000 for Q3 2025, slightly down from $3,545,000 in Q3 2024[25] Future Outlook - The company anticipates development goals to be achieved by mid-2028[19]